<DOC>
	<DOC>NCT01118936</DOC>
	<brief_summary>The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease. The aim of this part of the project is to study the effect of a daily magnesium supplement for COPD-patients</brief_summary>
	<brief_title>Daily Magnesium-treatment of Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<criteria>COPDpatients, grade moderatesevere (FEV1 3080 % of expected. FEV1/FVC &lt; 0,7). SeMg &gt; 2,00 mmol/L, smoking cessation less than 1 year prior to study start, submission to hospital within the last two years, submission to hospital with exacerbation during the study period, major changes in eating habits within three months prior to study start and during the study period of approx.one year various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Daily magnesium supplement</keyword>
	<keyword>EQ-5D</keyword>
</DOC>